ELISpot Path: SARS-CoV-2 (S1scan+SNMO) Human IFN-γ (ALP) 3420-4AST-P1-1 from Mabtech AB

Product Specs
ItemELISpot Path: SARS-CoV-2 (S1scan+SNMO) Human IFN-γ (ALP)
CompanyMabtech AB
Price Pricing Info Supplier Page View Company Product Page
Catalog Number3420-4AST-P1-1
Reactivityhuman
ApplicationsELISpot
Quantity1 plate
Detection TargetIFN-γ
NCBI Full Gene Nameinterferon gamma
NCBI Gene AliasesIFG, IFI, IMD69
Conjugate/Tag/LabelALP
TypeStreptavidin-ALP
Formatpre-coated strip plates
ComponentsSARS-CoV-2 S1 scanning pool,SARS-CoV-2 SNMO defined peptide pool,Anti-CD28 mAb,Biotinylated detection mAb (7-B6-1),Streptavidin-ALP,Anti-CD3 mAb,Substrate (BCIP/NBT-plus),Pre-coated strip clear plate (mAb 1-D1K)

Box 1233

Nacka Strand, SE-131 28

Sweden

Phone: +46 8 716 27 00
+46 8 716 27 01

(1) Spike-specific T-cell responses in patients with COVID-19 successfully treated with neutralizing monoclonal antibodies against SARS-CoV-2International Journal of Infectious DiseasesSeptember 16, 2022Salvatore Rotundo et al.nitrogen until use. Enzyme-linked immunoSpot assay Enzyme-linked immunospot (ELISpot) path kit (cod.3420-4AST-P1-1, Mabtech, Sweden) was used for the enumeration of PBMCs secreting interferon (IFN)-γ in response to

(2) mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include OmicronCell ReportsApril 12, 2022Hye Kyung Lee et al.SARS-CoV-2 Panel 23 (ACE2) Kit,Meso Scale Discovery,Cat# K15570U ELISpot Path: Human IFN-γ,Mabtech,Cat# 3420-4AST-P1-1 TruSeq Stranded mRNA Library Prep Kit,"Illumina,",Cat# RS-20020595 Luciferase assay,Promega,E4550 ,, Deposited

(3) Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA VaccinationFrontiers in ImmunologyFebruary 25, 2022Ayman Al Jurdi et al.cells were added to ELISpotPLUS plates pre-coated with anti-IFN-γ antibodies (Mabtech, catalog no. 3420-4AST-P1-1). The cells were stimulated with SARS-CoV-2 peptides from the S1 region of the spike protein at a concentration

(4) Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19CellOctober 1, 2020Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, Llewellyn-Lacey S, Kamal H, Bogdanovic G, Muschiol S, et al.

(6) An immunogenic personal neoantigen vaccine for patients with melanomaNatureJuly 13, 2017Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al.

(7) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensNatureNovember 27, 2014Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al.

(8) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assaysJournal of immunological methodsFebruary 1, 2002Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH.

(9) Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cellsJournal of immunological methodsMay 25, 1988Czerkinsky C, Andersson G, Ekre HP, Nilsson LA, Klareskog L, Ouchterlony O.

ELISpot Path: SARS-CoV-2 (S1scan+SNMO) Human IFN-γ (ALP) from Mabtech AB